Table 1 Relationship between AE2 expression and clinicopathological features of gastric cancer
From: Expression of AE1/p16 promoted degradation of AE2 in gastric cancer cells
Clinicopathological features | No.a | AE2 expression | P value | |
|---|---|---|---|---|
Negative no. (%) | Positive no. (%) | |||
Mean ages (years) | ||||
63.6 ± 12.8 | 174 | 119 | 55 | |
Age (years) | 0.6247 | |||
≤ 65 | 87 | 61 (70.11) | 26 (29.89) | |
> 65 | 87 | 58 (66.67) | 29 (33.33) | |
Gender | 0.4655 | |||
Male | 107 | 71 (66.36) | 36 (33.64) | |
Female | 67 | 48 (71.64) | 19 (28.36) | |
Differentiation | 0.0005 | |||
Well or Moderately | 72 | 39 (54.17) | 33 (45.83) | |
Poorly | 101 | 80 (79.21) | 21 (20.79) | |
Lymph metastasis | 0.7668 | |||
Negative | 39 | 26 (66.67) | 13 (33.33) | |
Positive | 133 | 92 (69.17) | 41 (30.83) | |
TNM staging | 0.0179 | |||
I | 20 | 9 (45.00) | 11 (55.00) | |
II–IV | 130 | 93 (71.54) | 37 (28.46) | |
Lauren classification | 0.0002 | |||
Intestinal type | 66 | 37 (56.06) | 29 (43.94) | |
Diffuse type | 82 | 69 (84.15) | 13 (15.85) | |